Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Paul Prescott Just Put GT Biopharma, Inc. (Nasdaq: GTBP)
On the Watchlist This Morning
—Friday, May 29, 2026
Get Our Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.
My Full Coverage On (GTBP) is Starting Right Now
Take A Look At (GTBP) This Morning While It’s Still Early…
May 29, 2026
(Nasdaq: GTBP) Just Hit Our Screen With Two Active Phase 1 Programs Underway
Dear Reader, This morning, Street Ideas has its eyes on a little-known biotech trending below $0.50 that recently made an approximate 77% move over the last month while remaining largely under the radar. GT Biopharma, Inc. (Nasdaq: GTBP) is developing a proprietary NK cell engager platform designed to activate the body’s natural killer cells directly in vivo, with active Phase 1 programs now underway in both hematologic malignancies and solid tumors. Following the recent first-patient dosing in the company’s GTB-5550 basket study, combined with anticipated clinical updates later this year and a projected runway through Q4 2026, GTBP has just landed at the top of the Street Ideas watchlist this morning—Friday, May 29, 2026. GTBP was around $.27 on April 29 and tapped $.48 on May 22, showcasing an approximate 77% move in less than a month, according to Barchart. 
What makes this setup stand out is the combination of near-term clinical timelines, recent momentum, and a platform aimed at several difficult-to-treat disease areas. With two active clinical programs and recent momentum behind it, GTBP is shaping up as a name to watch on Friday. About GT Biopharma, Inc. (Nasdaq: GTBP)
GT Biopharma, Inc. (Nasdaq: GTBP) is a San Francisco-based clinical-stage biopharmaceutical company developing immuno-oncology therapeutics based on its proprietary TriKE® (Tri-Specific NK Cell Engager) platform. Unlike CAR-T therapies — which require cells to be harvested and modified outside the body — GTBP’s approach is designed to harness and enhance the cancer-killing ability of a patient's own NK cells directly in vivo, without removing or modifying those cells prior to treatment. The company holds an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using the TriKE® technology. The TriKE® platform is built around a tri-specific molecule with three functional domains: an anti-CD16 nanobody that binds and activates NK cells via antibody-dependent cellular cytotoxicity (ADCC), an IL-15 crosslinker that promotes NK cell expansion and persistence at the tumor site, and an anti-tumor associated antigen (TAA) binding domain that directs NK cells to specific cancer markers. This modular architecture allows GTBP to efficiently adapt the platform across different tumor targets — a key design advantage. 
GTBP’s active pipeline includes three named TriKE® candidates: GTB-3650, a second-generation camelid nanobody TriKE® currently in an actively enrolling Phase 1 dose escalation trial for relapsed or refractory (r/r) CD33-expressing hematologic malignancies including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS); GTB-5550, a B7-H3-targeted TriKE® that recently entered Phase 1 clinical testing following dosing of the first patient in the company’s solid tumor basket study evaluating multiple B7-H3-expressing cancers; and GTB-7550, a CD19-targeted candidate in preclinical development for lupus and other autoimmune disorders. A Growing Market Primed for NK Cell Engager Innovation
The broader cancer immunotherapy market was valued at approximately $136B in 2025 and is projected to reach roughly $367B by 2035, growing at a compound annual growth rate (CAGR) of approximately 10.4%. Within that broader landscape, the NK cell therapeutics segment is expanding even faster — valued at $3.2B in 2024 and forecast to reach $8.6B by 2033. GTBP’s GTB-5550 program targets a portion of the estimated $362B global solid tumor market, according to the company’s January 2026 IND announcement. Following the recent dosing of the first patient in the GTB-5550 Phase 1 basket study, the program is now actively evaluating multiple B7-H3-expressing solid tumor indications. The trial is designed to include up to seven metastatic cancer cohorts: castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. Importantly, the dose escalation portion of the study is expected to focus primarily on prostate cancer patients before broader cohort expansion. The TriKE® mechanism is also designed to avoid some of the most severe side effects associated with competing modalities. CAR-T therapies are widely associated with cytokine release syndrome (CRS) and neurological complications stemming from T-cell hyperactivation. 
GTBP’s approach selectively activates NK cells rather than T cells, potentially offering a more tolerable safety profile — an important distinction in the immunotherapy landscape. Large pharmaceutical companies have already shown substantial interest in NK cell engager technologies. According to GT Biopharma’s May 2026 corporate presentation, both Sanofi and Gilead completed major NK cell engager transactions involving upfront and milestone payments exceeding $1B. Proof of Concept in the Clinic — and a Platform Moving
Into Solid Tumors
GTBP’s clinical foundation is not speculative — the company’s first-generation TriKE®, GTB-3550, completed a Phase 1 study in AML and MDS patients and demonstrated reproducible NK cell proliferation, activation, and persistence across all patients and all dose levels, with minimal clinically significant toxicity. In select patients, GTB-3550 showed reductions in CD33+ bone marrow blast levels: 33.3% in one patient, 61.7% in another, 63.6% in a third, and 50% in a fourth — encouraging early signals for a first-in-class modality at lower dose levels. Building on those results, GTBP’s second-generation candidate GTB-3650 incorporates camelid nanobody technology for improved potency, enhanced binding affinity, commercial manufacturing capabilities through Cytovance, and full proprietary ownership by GT Biopharma. The Phase 1 dose escalation trial for GTB-3650 remains actively enrolling, with additional updates anticipated in the second half of 2026 as enrollment progresses through dose escalation cohorts. Importantly, GT Biopharma’s platform has now expanded beyond hematologic malignancies and officially entered solid tumor testing with GTB-5550, following first-patient dosing in May 2026. GTB-5550 is the company’s B7-H3-targeted TriKE® candidate and represents the third TriKE® program to enter human trials. Financial Position: Funded Into Q4 2026
According to GTBP’s first quarter 2026 financial results, the company reported approximately $9M in cash as of March 31, 2026. Management anticipates this cash position will support operations through Q4 2026, covering both the ongoing GTB-3650 Phase 1 dose escalation trial and the recently initiated GTB-5550 Phase 1 basket trial in B7-H3-expressing solid tumors. The updated financial picture gives GTBP runway visibility as both clinical programs advance through dose escalation, with additional updates expected during the second half of 2026. 7 Reasons Why (GTBP) is Topping Our Watchlist This Morning—Friday, May 29, 2026…
1. Under the Radar: With a sub-$20M market cap, GTBP remains a smaller clinical-stage biotech name.
2. Recent Momentum: After an approximate 59% move in under a week, GTBP has fresh momentum behind it. 3. Solid Tumors: Following first-patient dosing, GTBP has expanded GTB-5550 into Phase 1 solid tumor testing. 4. Active Trial: The GTB-3650 Phase 1 dose escalation study gives GTBP an ongoing clinical timeline. 5. 2H Updates: Additional clinical updates are expected in the second half of 2026, keeping GTBP on watch. 6. Q4 Runway: Management expects GTBP’s cash position to support operations through Q4 2026. 7. Pipeline Depth: With three named TriKE® candidates, GTBP spans blood cancers, solid tumors, and autoimmune disease.
Take A Look At (GTBP) This Morning While It’s Still Early…
Between the recent momentum, active clinical enrollment, upcoming Q3 2026 data timeline, and a second FDA-cleared program preparing to enter the clinic, (GTBP) is beginning to draw attention at a time when several important developments appear to be lining up simultaneously. The company’s TriKE® platform also gives (GTBP) exposure across multiple disease areas, while current funding guidance through Q4 2026 provides visibility into the next stage of clinical execution. For a biotech still operating with a market cap below $20M, the setup is difficult to ignore. We have all eyes on (GTBP) this morning. Take a look at (GTBP) while it’s still early. And watch for my next update, it could be hitting before the bell. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter
|
